Amyris, a leader in biomanufacturing, has announced its acquisition of Oobli, a company known for its innovative sweet protein technology. This acquisition, set to conclude in the coming weeks, represents a strategic expansion for Amyris, combining Oobli’s expertise in protein development with Amyris’s existing fermentation capabilities. This move is significant for companies in the architecture, engineering, construction, and manufacturing (AECM) sectors as it underscores the growing importance of biomanufactured solutions in reducing costs and enhancing sustainability.
What Happened
The acquisition of Oobli by Amyris marks a pivotal moment in the biomanufacturing industry. Oobli, which has developed fermentation processes for sweet proteins found in fruits and berries, will integrate its technology with Amyris’s advanced strain engineering and manufacturing capabilities. This merger will continue to support Oobli’s existing customer commitments and partnerships, ensuring a seamless transition for its commercial sweet protein portfolio. Oobli’s products, which include ingredients like brazzein, monellin, and thaumatin, are designed to help food and beverage companies significantly reduce sugar content while maintaining sweetness. These ingredients have been recognized as safe for use and are poised for application in a wide range of products, including beverages, dairy, sports nutrition, and confectionery.
The acquisition aligns with Amyris’s recent expansion of its fermentation facility in Barra Bonita, Brazil, which occurred earlier in 2026. This facility expansion is part of Amyris’s broader strategy to enhance its production capabilities and diversify its offerings in protein- and peptide-based ingredients. By integrating Oobli’s technology, Amyris aims to scale its existing sweet protein products and explore new market applications in personal care, flavors, fragrances, and agriculture.
What This Means for Your Business
For decision-makers in the AECM sectors, this acquisition highlights the potential for innovative biomanufactured solutions to meet evolving consumer demands for healthier, sustainable products. The integration of Oobli’s sweet protein technology into Amyris’s platform could lead to new opportunities for companies to reduce costs and improve sustainability in their supply chains. By leveraging Amyris’s expanded manufacturing capabilities, businesses can expect enhanced access to biomanufactured ingredients that align with clean label trends and sugar reduction initiatives. This acquisition also emphasizes the importance of staying informed about advancements in biomanufacturing technologies, which can provide competitive advantages and drive ROI through improved product offerings.
What US Operators Should Watch
US operators should closely monitor the progress of the Amyris-Oobli integration, as it may lead to new procurement opportunities and partnerships in the biomanufacturing space. Additionally, companies should be aware of potential regulatory developments concerning the use of biomanufactured sweet proteins in various industries. With the transaction expected to close soon, businesses should prepare for potential shifts in the market landscape and consider how these advancements could impact their operations and product development strategies.
Source: https://pulse2.com/amyris-oobli-acquisition-adds-sweet-protein-technology-to-biomanufacturing-platform/. Read the original story ->
Is your firm ready for what’s next?
VisioneerIT helps AECM and government contractors modernize operations, achieve compliance, and implement AI.
Explore VisioneerIT Solutions →